The United States market has experienced a notable upswing, climbing 1.5% in the last week and achieving a 33% increase over the past year, with earnings anticipated to grow by 16% annually in the coming years. In this context of robust market performance, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to capitalize on these favorable conditions.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|
Super Micro Computer | 20.86% | 27.98% | ★★★★★★ |
Sarepta Therapeutics | 23.61% | 43.75% | ★★★★★★ |
TG Therapeutics | 28.39% | 43.54% | ★★★★★★ |
Invivyd | 42.91% | 70.39% | ★★★★★★ |
Ardelyx | 27.19% | 66.44% | ★★★★★★ |
Amicus Therapeutics | 20.33% | 62.45% | ★★★★★★ |
Travere Therapeutics | 27.18% | 69.88% | ★★★★★★ |
MediaAlpha | 22.72% | 61.31% | ★★★★★★ |
Seagen | 22.57% | 71.80% | ★★★★★★ |
ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 253 stocks from our US High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: CleanSpark, Inc. is a company that engages in bitcoin mining operations across the Americas with a market capitalization of $2.43 billion.
Operations: The company generates revenue primarily from its bitcoin mining operations, totaling $342.21 million. Its financial performance is closely tied to the efficiency and scale of these mining activities.
CleanSpark, with its projected annual revenue growth at a robust 39.4%, significantly outpaces the broader U.S. market's 8.8% expansion rate, positioning itself as a dynamic player in the tech sector despite current unprofitability. The company's focus on innovation is underscored by its R&D expenditure trends, which have been strategically aligned to bolster future profitability; notably, earnings are anticipated to surge by an impressive 94.9% annually. Recent operational updates further highlight resilience and adaptability—post-Hurricane Helene, CleanSpark swiftly resumed operations and achieved a hashrate of 28.7 EH/s, demonstrating robust recovery capabilities and operational efficiency in crisis scenarios.
NasdaqCM:CLSK Revenue and Expenses Breakdown as at Oct 2024
Simply Wall St Growth Rating: ★★★★★★
Overview: TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that specializes in acquiring, developing, and commercializing novel treatments for B-cell mediated diseases globally, with a market cap of $3.18 billion.
Operations: TG Therapeutics focuses on the biotechnology sector, generating $346.72 million in revenue from its innovative treatments for B-cell mediated diseases.
TG Therapeutics, showcasing a notable 43.5% forecasted annual earnings growth, significantly outstrips the broader U.S. market's expectations. This performance is underpinned by a robust 28.4% predicted revenue increase annually, reflecting its strategic focus on innovative treatments in biotechnology—a sector marked by rapid advancements and high investment returns potential. The company's commitment to R&D is evident from its recent FDA clearance for Azercabtagene Zapreleucel trials, emphasizing its dedication to addressing progressive forms of multiple sclerosis with cutting-edge therapies. These developments not only enhance TG Therapeutics' market position but also demonstrate potential for sustained growth and investor interest in an evolving healthcare landscape.
NasdaqCM:TGTX Revenue and Expenses Breakdown as at Oct 2024
Simply Wall St Growth Rating: ★★★★★☆
Overview: Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing therapies for rare neuroendocrine diseases, with a market capitalization of $3.05 billion.
Operations: Rhythm Pharmaceuticals focuses on developing and commercializing therapies for patients with rare neuroendocrine diseases, generating $101.78 million in revenue from these activities. The company operates within the biopharmaceutical sector, emphasizing innovative treatments for niche medical conditions.
Rhythm Pharmaceuticals stands out with a projected annual revenue growth rate of 44%, significantly surpassing the U.S. market average of 8.8%. This growth is fueled by innovative treatments in rare genetic disorders linked to obesity, underscored by recent FDA prioritizations and expansions in drug approvals for younger demographics. Despite current unprofitability, earnings are expected to surge by 62.9% annually, reflecting strong potential as the company transitions towards profitability within three years. R&D commitment is evident with substantial investments leading to significant advancements in precision medicine for obesity management, positioning Rhythm at the forefront of addressing underserved medical needs through targeted therapies.
NasdaqGM:RYTM Earnings and Revenue Growth as at Oct 2024
Make It Happen
Seeking Other Investments?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqCM:CLSK NasdaqCM:TGTX and NasdaqGM:RYTM.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]